Corporate Governance
UCB Governance
The Company is administered by a Board of Directors and run by an Executive Committee, whose respective functions and responsibilities are clearly defined in the Corporate Governance Charter.
UCB SA/NV has adopted the 2020 edition of the Belgian Code of Corporate Governance as its reference Code taking into account the specific international aspects of the Company. As part of these rules, UCB SA/NV, as a listed company, has adopted a Corporate Governance Charter and a Code of Conduct, including a Dealing Code.
The Corporate Governance Charter established by the Board of Directors aims at providing a comprehensive and transparent disclosure of the Company’s governance. It defines the system of checks and balances between the shareholders/investors, the Board and the management to shape an efficiently functioning company, ideally geared to produce long-term sustainable value for all the Company’s stakeholders. It will be continuously updated as required.
Articles of Association
| Title | Format | Download |
|---|---|---|
|
Articles of Association (ENG)
|
PDF
|
|
|
Articles of Association (FR)
|
PDF
|
|
|
Articles of Association (NL)
|
PDF
|
Special Reports of the Board
| Title | Format | Download |
|---|---|---|
|
Special report of the Board - 27 February 2024 (ENG)
|
PDF
|
|
|
Special report of the Board - 27 February 2024 (FR)
|
PDF
|
|
|
Special report of the Board - 27 February 2024 (NL)
|
PDF
|
Remuneration Policy 2024
| Title | Format | Download |
|---|---|---|
|
Remuneration Policy 2024 (ENG)
|
PDF
|
|
|
Remuneration Policy 2024 (FR)
|
PDF
|
|
|
Remuneration Policy 2024 (NL)
|
PDF
|
Related Press Releases
Corporate Governance Charter
UCB Dealing Code
Code of Conduct
Board of Directors
To enhance the overall effectiveness of the Board by ensuring focus, oversight and monitoring of sensitive areas, the Board has created three specialist committees.
Composition
(Updated: April 2024)
14 Members
10 Independent Directors (71%)
8 Nationalities
6 Women (43%)
4-Year Mandate
Age Limit: 70
Jonathan Peacock
Independent Director
Chair of the Board
First appointed in 2021
End of term in 2025
Charles-Antoine Janssen
Director
Vice-chair of the Board
Member of the GNCC
First appointed in 2012
End of term in 2028
Jean-Christophe Tellier
Executive Director
First appointed in 2014
End of term in 2026
Maëlys Castella
Independent Director
Member of the Audit Committee
First appointed in 2023
End of term in 2027
Kay Davies
Independent Director
Member of the Scientific Committee
Chair of the GNCC
First appointed in 2014
End of term in 2026
Pierre Gurdjian
Independent Director
Member of the GNCC
First appointed in 2016
End of term in 2028
Susan Gasser
Independent Director
Member of the Scientific Committee
First appointed in 2021
End of term in 2025
Cédric van Rijckevorsel
Director
Member of the Audit Committee
First appointed in 2014
End of term in 2026
Ulf Wiinberg
Independent Director
Member of the GNCC
First appointed in 2016
End of term in 2028
Nefertiti Greene
Independent Director
Member of the GNCC
First appointed in 2024
End of term in 2028
Dolca Thomas
Independent Director
Member of the Scientific Committee
First appointed in 2024
End of term in 2028
Rodolfo Savitzky
Independent Director
Chair of the Audit Committee
First appointed in 2024
End of term in 2028
Executive Committee
We have adapted an organizational structure on four pillars around which we create value for each patient, centered by our focus and integrated across functional teams around different patient populations.
Composition
(Updated: July 2024)
8 members
5 nationalities
4 women (50%)
Jean-Christophe Tellier
Chief Executive Officer &
Chairman of the Executive Committee
Joined UCB in 2011
Appointed CEO in 2015
Emmanuel Caeymaex
Executive Vice President
Chief Commercial Officer
Joined UCB in 1994
Appointed in 2015
Sandrine Dufour
Executive Vice President
Chief Financial Officer
Joined UCB in July 2020
Appointed in July 2020
Jean Luc Fleurial
Executive Vice President
Chief Human Resources Officer
Joined UCB in 2017
Appointed in 2017
Fiona du Monceau
Executive Vice President
Patient Evidence
Joined UCB in 2024
Appointed in 2024
Kirsten Lund-Jurgensen
Executive Vice President
Patient Supply
Joined UCB in 2019
Appointed in 2019
Alistair Henry
Executive Vice President &
Chief Scientific Officer
Joined UCB in 2004
Appointed in 2024
Denelle J. Waynick Johnson
Executive Vice President &
General Counsel
Joined UCB in 2023
Appointed in 2023
Shareholders and Shareholder Meetings
Find out about UCB shareholders, their transparency notifications and our shareholder meetings on the dedicated webpage.
Contact UCB IR Team
investor-relations@ucb.com or a specific team member:
Antje Witte, Head of Investor Relations
Tel: +32 2 559 9414
E-mail: Antje.Witte@ucb.com
Sahar Yazdian, Investor Relations Lead
Tel: +32 2 559 9137
E-mail: Sahar.Yazdian@ucb.com
UCB IR App
